Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects

NCT02147925 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of three diabetes medications—liraglutide, sitagliptin, and glargine—on liver fat levels in adults with type 2 diabetes and non-alcoholic fatty liver disease.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 75 people

Who can join Ages 30–75 · all sexes

Timeline Started 2014-08 · est. completion 2017-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02147925 ↗

Description as written by the study sponsor.

The aim of this study is to explore the effectiveness of liraglutide combined with metformin in non-alcoholic fatty-liver disease patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and insulin glargine in combination with metformin.

Treatments tested

Liraglutide combined with metformin also known as Victoza®, Novo Nordisk Drug

Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
Insulin glargine combined with metformin also known as Lantus®, Sanofi Drug

The initial dose will be 0.2 unit/kg/d
Sitagliptin combined with metformin also known as Januvia®, Merck & Co. Inc. Drug

The dose throughout the study will be 100mg per day.

Main thing measured	Intrahepatic lipids (IHL)
Sponsor	Sun Yat-sen University
Conditions studied	Non-alcoholic Fatty Liver Disease
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02147925 ↗